3‐Year Outcomes of Adults with Relapsed or Refractory B‐cell Acute Lymphoblastic Leukemia Treated with Brexu‐cel in ZUMA‐3 by Age, Prior Therapies, and Subsequent Transplant
B. D. Shah,R. D. Cassaday,J. H. Park,R. Houot,O. O. Oluwole,A. C. Logan,N. Boissel,T. Leguay,M. R. Bishop,M. S. Topp,K. M. O’Dwyer,M. R. Baer,G. J. Schiller,M. Abedi,M. C. Minnema,P. Stiff,L. Zhou,T. Hadjivassileva,R. Damico Khalid,A. Armin Ghobadi
DOI: https://doi.org/10.1002/hon.3164_385
IF: 4.85
2023-01-01
Hematological Oncology
Abstract:Background: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the US for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and in the EU for adults ≥26 years with R/R B-ALL based on positive results of ZUMA-3. After 3-years follow-up in ZUMA-3, brexu-cel demonstrated an overall complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate of 71% and a median overall survival (OS) of 26.0 mo in all treated pts (N = 55) and 38.9 mo in pts with CR (n = 31; Shah et al. EU CAR T 2023. Abstract 34). Here we report 3-years outcomes by age, prior therapies, and subsequent allogeneic stem cell transplant (alloSCT). Methods: Pts (≥18 years) had R/R B-ALL and received 1 brexu-cel infusion (1×10⁶ CAR T cells/kg) following leukapheresis and conditioning chemotherapy. The primary endpoint was overall CR/CRi rate per independent review. Post hoc subgroup analyses were exploratory, with descriptive statistics reported. Results: As of July 23, 2022, the median follow-up in Phase 2 (N = 55) was 38.8 mo (range, 32.7–44.6). The CR/CRi rate (95% CI) was 67% (35–90) for pts <26 years (n = 12) and 72% (56–85) for pts ≥26 years (n = 43). The median (95% CI) OS was 28.6 mo (0.6-not estimable [NE]) for pts <26 years and 34.1 mo (15.9-NE) for pts ≥26 years. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 92% of pts <26 years and in 88% of pts ≥26 years. For pts with 1 prior therapy (n = 10), the CR/CRi rate was 90% (95% CI, 55–100) and for pts with ≥2 prior therapies (n = 45), the CR/CRi rate was 67% (95% CI, 51–80); medians (95% CI) for OS were not reached (NR; 2.1-NE) and 25.6 mo (14.2–38.9), respectively. The incidence of Grade ≥3 TRAEs was 90% for pts with 1 prior therapy and 89% for pts with ≥2 prior therapies. The CR/CRi rates (95% CI) for pts with (n = 25) and without (n = 30) prior blinatumomab (blina) were 60% (39–79) and 80% (61–92). The median (95% CI) OS was 14.2 mo (3.2–26.0) for pts with prior blina and NR (18.6-NE) for pts without prior blina; Grade ≥3 TRAEs occurred in 80% and 97% of pts, respectively. For responders (CR/CRi) who did (n = 10) or did not (n = 29) proceed to subsequent alloSCT, the median (95% CI) OS was NR (7.6-NE) and 38.9 mo (18.6-NE), respectively. Similar efficacy results were observed in a pooled subgroup analysis of Phase 1 and 2 pts treated at the pivotal dose (N = 78), with a median follow-up of 41.6 mo (range, 32.7–70.3). Conclusions: Adults with R/R B-ALL benefitted from brexu-cel, regardless of age, number of prior therapies, prior blina exposure, or subsequent alloSCT status. Survival appeared longer in pts with fewer prior therapies and in blina-naïve pts; however, small pt numbers and unmatched baseline characteristics limit interpretation of these results. Additional studies are needed to determine the impact of prior therapies and/or subsequent alloSCT on outcomes of pts who receive brexu-cel. Encore Abstract - previously submitted to ASCO 2023 and EHA 2023 The research was funded by: The research was funded by: Kite, a Gilead Company Keywords: Aggressive B-cell non-Hodgkin lymphoma, Cellular therapies, Immunotherapy Conflicts of interests pertinent to the abstract. B. D. Shah Consultant or advisory role: Adaptive, Amgen, Autolus, Beigene, BMS, Century Therapeutics, Deciphera, Jazz, Kite, a Gilead Company, Lilly, Novartis, Precision Biosciences, Pfizer, and Takeda Research funding: Jazz Pharmaceuticals, Kite and Servier Other remuneration: PeproMene Bio R. D. Cassaday Employment or leadership position: (Immediate family member): Seagen Consultant or advisory role: Amgen and Kite, a Gilead Company Stock ownership: (Immediate family member): Seagen Honoraria: Amgen, Jazz, Kite, and Pfizer Research funding: Amgen, Kite, Merck, Pfizer, Servier, and Vanda Educational grants: Kite Other remuneration: Autolus (independent review committee) and Pepromene Bio (DSMB) J. H. Park Consultant or advisory role: AstraZeneca, Kite, a Gilead Company, and Novartis Research funding: Amgen, Genentech, and Juno R. Houot Consultant or advisory role: Kite, a Gilead Company and Gilead Honoraria: ADC therapeutics, Bristol-Myers Squibb, Celgene, Gilead Sciences, Janssen, Kite, MSD, and Novartis N. Boissel Consultant or advisory role: Amgen, Kite, a Gilead Company, and Novartis Honoraria: Amgen, Kite, and Novartis Research funding: Amgen Other remuneration: Expert testimony for Amgen T. Leguay Consultant or advisory role: Amgen, Incyte, and Servier Honoraria: Amgen, Incyte, Kite, a Gilead Company, and Servier M. R. Bishop Consultant or advisory role: Novartis, Kite/Gilead, Bristol-Myers Squibb, Sana Bio, CRISPR Therapeutics Honoraria: Incyte, Bristol-Myers Squibb, Sanofi, ADC Therapeutics Other remuneration: Speakers' bureau participation for Incyte, Bristol-Myers Squibb, Sanofi, and ADC Therapeutics M. S. Topp Consultant or advisory role: AstraZeneca, Bristol Myers Squibb, GenMaB, Kite, a Gilead Company, and Roche Research funding: Kite, Regeneron, Roche, and Takeda Educational grants: Janssen and Kite M. R. Baer Research funding: Abbvie, Ascentage, Kite, a Gilead company, Kura, and Takeda G. J. Schiller Honoraria: Kite, a Gilead Company Research funding: Kite Other remuneration: Speakers' bureau participation for Kite M. Abedi Consultant or advisory role: Celgene Honoraria: Celgene Other remuneration: Speakers’ bureau participation for Abbvie, Bristol Myers Squibb, Celgene, and Kite, a Gilead Company M. C. Minnema Consultant or advisory role: (To your institution): Bristol Myers Squibb, CDR-life, GSK, and Janssen-Cilag Research funding: (To your institution): Beigene Other remuneration: Speaker's bureau participation for WebMD P. Stiff Consultant or advisory role: MorphoSys and CRISPR Therapeutics Honoraria: MorphoSys and CRISPR Therapeutics Research funding: Amgen, Gamida Cell, Pfizer, Karyopharm, Gilead Sciences, Incyte, Seagen, and Cellectar L. Zhou Employment or leadership position: Kite, a Gilead Company Stock ownership: AbbVie RSU T. Hadjivassileva Employment or leadership position: Kite, a Gilead Company Stock ownership: Kite R. Damico Khalid Employment or leadership position: Kite, a Gilead Company Stock ownership: Kite Educational grants: Kite A. Armin Ghobadi Consultant or advisory role: Amgen, Atara, BMS, CRISPR therapeutics, Kite, a Gilead Company, and Wugen Inc. Honoraria: Kite Research funding: Amgen, Genentech, and Kite